Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
Jeito Capital co-leads EUR 50 million financing inCatalYm, a clinical-stage biopharma companydeveloping novel immunotherapies for patients with cancer
- Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital
- CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients
- Jeito Capital strengthens its strong and diversified portfolio with first German investment
Paris, France, November 22nd2022 - Jeito Capital ("Jeito"), a leading independent international private equity firm dedicated to healthcare and biopharma, announced today that it has co-led a EUR 50 million Series C financing round in CatalYm, a clinical-stage biopharmaceutical company developing novel immunotherapies to fight cancer. The oversubscribed financing was co-led by Brandon Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures, and Coparion. CatalYm was founded in 2016 as a spin-off from Würzburg University and is based in Munich (Germany).
CatalYM’s lead candidate, visugromab is a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). It is currently in Phase 2 clinical studies in patients with solid tumors that are relapsed/refractory to prior anti-PD1/-PD-L1 treatment. GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue.
Proceeds from the financing will primarily be used to expand the Phase 2 clinical development program of visugromab. This expansion is based on convincing efficacy and durability results in advanced, last-line patients in Phase 1 and continued positive clinical responses in the ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector cell Relocation Phase 2). The expanded Phase 2 clinical studies will enroll patients at clinical centers in Europe and the United States.
Jeito selected CatalYm in line with its investment strategy to support the development of the most promising European Biopharma with growth and acceleration potential. Dr. Andreas Wallnoefer, Partner at Jeito Capital will join CatalYM’s Board of Directors.
Throughout 2022, Jeito has continued to build a portfolio of innovative companies across diverse therapeutic areas and across stages of development with the strong potential to improve the lives of patients. With CatalYm, Jeito makes its first investment in Germany, which has a very dynamic and internationally recognized biopharma ecosystem. Jeito closed its Jeito I fund at €534 million in September 2021 and has to date invested in high-quality biopharma companies with the potential to become market leaders in France, Belgium, Denmark, Switzerland, the UK and the US.
Dr Rafaèle Tordjman, MD, PhD,Founder and CEO of Jeito, commented: “We are thrilled to co-lead this new round of financing in CatalYm to further accelerate its clinical development and support its world leading research for the benefit of severely ill patients with no satisfying therapeutic solution. Jeito is committed to supporting and accelerating the development of the most promising European biopharma companies. CatalYm has the potential of growth and acceleration for patients, which is a core value for Jeito. Jeito selected this clinical stage company that has a promising new therapy approach to treat cancer, which has already demonstrated the first clinical signs of activity for severe relapsed patients. We look forward to working with the experienced CatalYm team.”
Dr. Andreas Wallnoefer, Partner at Jeito, added: “Visugromab has shown promising results in enhancing the immune response to fight cancer in its first clinical trials, resulting in several impressive responses in patients with advanced tumors and last line treatments. The drug has great potential to improve patients’ lives and become part of cancer immune therapy regimens given its important efficacy profile and good tolerability.”
Dr. Phil L’Huillier, Chief Executive Officer at CatalYm, concluded: “The success of our Series C financing, based on strong clinical data, is a further validation that visugromab is emerging as a new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape. We deeply value the commitment of our new and existing investors, which will enable further clinical development moving our lead program towards pivotal studies.”
About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.
CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors. CatalYm’s lead program visugromab is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment horizon for current and future immunotherapies.
About visugromab (CTL-002)
Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 secretion by the tumor has been shown to prevent T cell migration into the tumor and suppresses T cell function and the adaptive immune response in the tumor microenvironment. This enables the tumor to evade the immune system and become resistant to standard of care and current immunotherapy approaches such as checkpoint inhibitors. Visugromab counteracts these immuno-suppressive mechanisms by neutralizing GDF-15, enhancing the infiltration of immune cells into the tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells.
For further information please contact:
Assia Mouhout, EA
Tel : +33 6 76 49 37 94
Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam
Tel: +44 (0) 20 3709 5700
Tel : +33 6 76 73 57 31
Dr. Phil L’Huillier, CEO
Dr. Stephanie May
Phone: +49 171 185 56 82
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
The Saikyo Bank Partners with nCino to Enhance Operational Efficiency and Customer-Centric Services29.2.2024 00:00:00 CET | Press release
Japanese regional bank selects nCino to create a customer-driven mortgage lending experience by streamlining processes and systems onto a single platform TOKYO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that The Saikyo Bank, Ltd. (Saikyo), a $20B-asset regional bank in Japan, will implement nCino to improve operational efficiencies and customer convenience. Saikyo will start its single platform journey with nCino by introducing the technology to its mortgage operations. The adoption of nCino's platform aims to streamline Saikyo's mortgage business, from reception, screening, case management and electronic contracting to the execution of mortgage loan operations, allowing the Bank to improve efficiency and customer experience. Leveraging nCino's platform, the Bank will be able to increase the time that employees spend with customers by reducing administrative tasks, as well as prov
Change in the Board of Anoto28.2.2024 23:40:00 CET | Press release
Stockholm, 28 February 2024 – Anoto Group AB (publ) (“Anoto” or the “Company”) announces that Hans Haywood (former CEO of Anoto) and Pedro Pinto has requested their own resignation from the board of Anoto with immediate effect. Anoto board will still consist of Dennis Song as the chairman of the board and Injoon Chung, and is therefore not quorum until the EGM scheduled to be held on March 8, 2024 elects new board members. For further information contact: Dennis Song, Chairman of the Board For more information about Anoto, visit www.anoto.com or email firstname.lastname@example.org Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm About Anoto Group Anoto is a publicly held Swedish technology company known globally for innovation in the area of information-rich patterns and the optical recognition of those patterns. It is a leader in digital writing and drawing solutions, having historically used its proprietary technology to develop smartpens and related software. These smartpen
Förändringar i Anotos styrelse28.2.2024 23:40:00 CET | Pressemelding
Stockholm, 28 februari 2024 – Anoto Group AB (publ) ("Anoto" eller "Bolaget") meddelar att Hans Haywood (tidigare VD för Anoto) och Pedro Pinto har begärt eget utträde från styrelsen i Anoto med omedelbar verkan. Anotos styrelse kommer fortfarande att bestå av Dennis Song, som styrelsens ordförande, och Injoon Chung, och är därför inte beslutför förrän den extra bolagsstämma som planeras hållas den 8 mars 2024 väljer nya styrelseledamöter. För ytterligare information kontakta: Dennis Song, styrelseordförande för Anoto För mer information om Anoto, please visit www.anoto.com eller email email@example.com Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm Om Anoto Group Anoto är ett börsnoterat svenskt teknikföretag, som är känt i hela världen för innovationer rörande informationsrika mönster och optisk igenkänning av dessa mönster. Företaget är ledande när det gäller lösningar för digitalt skrivande och ritande, och har historiskt sett använt sin egenutvecklade teknol
Vow ASA: Full year and second half of 2023 results28.2.2024 23:11:51 CET | Press release
Oslo, 28 February 2024: Vow ASA (OSE: VOW) revenues for the full year 2023 were NOK 918.5 million, a 17 per cent increase from the year before. EBITDA before non-recurring items was negative NOK 23.4 million for the full year. In addition, the company recorded non-recurring items of negative NOK 31.3 million, mainly related to non-cash balance sheet clean-up in contract accruals. This resulted in a negative EBITDA for the year of NOK 54.7 million versus a positive NOK 85.5 million in 2022. “The year 2023 was a year of high activity and revenue. A large number of projects were successfully delivered. Activity in aftersales was increasing. We also secured important new contracts and moved into position for new projects in new industry verticals,” said Henrik Badin, CEO of Vow ASA. At the end of 2023, the order backlog was NOK 1 034 million and another NOK 921 million in options. The backlog and options are providing visibility for revenues and good margins well into 2025/26. “We have als
European Energy A/S: Notice to convene ordinary general meeting28.2.2024 23:08:42 CET | Press release
Company announcement 7/2024 (28.02.2024) The Board of Directors of the Company hereby convenes an ordinary general meeting of the Company, to be held on: Thursday 14 March 2024 at 09:30 CET at the address of the Company, Gyngemose Parkvej 50, 2860 Søborg, Denmark and electronically on Teams Agenda: Election of Chair of the Annual General Meeting.Report on the activities of the Company.Presentation of the annual report with the auditors’ report for approval and discharge of the Board of Directors and the Executive Board.Resolution on the appropriation of profit or treatment of loss according to the approved annual report.Election of members to the Board of Directors.Decision regarding remuneration to the Board of Directors for the financial year 2024. Amendments to the article of association.Election of Auditor(s).AOB. Attachment Notice to convene ordinary general meeting